-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ZimVie (NASDAQ:ZIMV) Now Covered by Analysts at Barclays
ZimVie (NASDAQ:ZIMV) Now Covered by Analysts at Barclays
Barclays assumed coverage on shares of ZimVie (NASDAQ:ZIMV – Get Rating) in a report released on Wednesday morning, The Fly reports. The brokerage issued an underweight rating and a $9.00 target price on the stock.
ZimVie Stock Performance
NASDAQ:ZIMV opened at $8.21 on Wednesday. The stock has a 50-day moving average price of $8.65 and a 200 day moving average price of $13.42. The company has a current ratio of 2.51, a quick ratio of 1.48 and a debt-to-equity ratio of 0.76. ZimVie has a 12-month low of $6.67 and a 12-month high of $50.40.
Get ZimVie alerts:ZimVie (NASDAQ:ZIMV – Get Rating) last announced its earnings results on Wednesday, November 9th. The company reported $0.49 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.22. ZimVie had a negative return on equity of 2.75% and a negative net margin of 9.96%. The firm had revenue of $214.58 million during the quarter, compared to analysts' expectations of $214.83 million. On average, sell-side analysts expect that ZimVie will post 1.95 earnings per share for the current fiscal year.
Hedge Funds Weigh In On ZimVie
A number of large investors have recently bought and sold shares of the business. Point72 Hong Kong Ltd purchased a new stake in shares of ZimVie in the third quarter valued at approximately $27,000. US Bancorp DE purchased a new position in shares of ZimVie during the third quarter worth $36,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of ZimVie during the third quarter worth $46,000. Strs Ohio acquired a new stake in shares of ZimVie in the third quarter valued at $47,000. Finally, Tower Research Capital LLC TRC acquired a new stake in shares of ZimVie in the third quarter valued at $47,000. Institutional investors and hedge funds own 74.62% of the company's stock.About ZimVie
(Get Rating)
ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.
Featured Articles
- Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.
Barclays assumed coverage on shares of ZimVie (NASDAQ:ZIMV – Get Rating) in a report released on Wednesday morning, The Fly reports. The brokerage issued an underweight rating and a $9.00 target price on the stock.
據The Fly報道,巴克萊在週三上午發佈的一份報告中對ZimVie(納斯達克:ZIMV-GET評級)的股票進行了報道。該經紀公司對該股發佈了減持評級和9.00美元的目標價。
ZimVie Stock Performance
ZimVie股票表現
NASDAQ:ZIMV opened at $8.21 on Wednesday. The stock has a 50-day moving average price of $8.65 and a 200 day moving average price of $13.42. The company has a current ratio of 2.51, a quick ratio of 1.48 and a debt-to-equity ratio of 0.76. ZimVie has a 12-month low of $6.67 and a 12-month high of $50.40.
納斯達克:ZIMV週三開盤報8.21美元。該股的50日移動均線價格為8.65美元,200日移動均線價格為13.42美元。該公司的流動比率為2.51,速動比率為1.48,債務權益比率為0.76。ZimVie的12個月低點為6.67美元,12個月高位為50.40美元。
ZimVie (NASDAQ:ZIMV – Get Rating) last announced its earnings results on Wednesday, November 9th. The company reported $0.49 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.22. ZimVie had a negative return on equity of 2.75% and a negative net margin of 9.96%. The firm had revenue of $214.58 million during the quarter, compared to analysts' expectations of $214.83 million. On average, sell-side analysts expect that ZimVie will post 1.95 earnings per share for the current fiscal year.
津維(納斯達克:ZIMV-GET評級)上一次公佈財報是在11月9日星期三。該公司公佈本季度每股收益為0.49美元,比分析師普遍預期的0.27美元高出0.22美元。ZimVie的淨資產回報率為負2.75%,淨利潤率為負9.96%。該公司本季度營收為2.1458億美元,高於分析師預期的2.1483億美元。賣方分析師平均預計,ZimVie本財年每股收益將達到1.95美元。
Hedge Funds Weigh In On ZimVie
對沖基金對ZimVie的看法
About ZimVie
關於ZimVie
(Get Rating)
(獲取評級)
ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.
ZimVie公司是一家醫療技術公司,開發、製造和提供一系列產品和解決方案,旨在治療一系列脊柱疾病,並在全球範圍內支持牙齒替換和修復程式。它提供牙科植入系統、假體和基臺產品、手術器械和套件;骨移植、屏障膜、同種異體移植和膠原傷口護理產品;口腔內掃描儀;虛擬治療計劃服務、指導性手術解決方案、CAD/CAM工作流程系統、患者特定的修復部件和口腔內掃描儀,以及用於各種脊柱程式、生物製劑和骨癒合技術的脊柱融合植入物和器械。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
- 免費獲取StockNews.com關於ZimVie的研究報告(ZIMV)
- Lucid Motors面臨的現實可能會給看漲的看法蒙上陰影
- 機構將Rite Aid的股票跌至谷底
- 這就是為什麼你應該避開聯盟快遞的反彈
- 維京治療公司股票為何暴漲
- 耐克公司業績和前景走高
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.
接受ZimVie Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對ZimVie和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧